Compared to the EXTREME regimen, pembrolizumab monotherapy improved overall survival in patients whose tumors expressed PDL1 and pembrolizumab with chemotherapy improved overall survival in all patients, irrespective of tumor PDL1 expression. This evidence concerns the gene CD274 and neoplasm.